6:17 Minutes ASTCT 2023 Guidelines: Prevention of CMV infection and disease after HCT ASTCT 2023 Guidelines: Prevention of CMV infection and disease after HCT BACK TO WEBCASTS MY-CYT-00108 June/2022
52:19 Minutes - 2 Chapters 1L Advanced Esophageal Cancer: Entering a New Survival Horizon BACK TO WEBCASTS MY-PDO-00044 Oct/2022
52:19 Minutes - 1 Chapter Thor’s Hammer: Is it worthy against Covid-19? Thor's Hammer: Is it worthy against Covid-19? BACK TO WEBCASTS MY-LAG-00063 Sep/2022
66:18 Minutes - 4 Chapters Unlocking New Paradigm in the Treatment of Metastatic TNBC BACK TO WEBCASTS MY-OBR-00021 Apr/2022
39 Minutes - 3 Chapters Personalizing Treatment of M/uR HNSCC with Immune Checkpoint Inhibitor BACK TO WEBCASTS MY-OHN-00015 Apr/2022
35:00 Minutes - 3 Chapters Redefining Survival Expectation for Relapsed or Refractory Classical Hodgkin Lymphoma
37:52 Changing Paradigm in Management of CMV Changing Paradigm in Management of CMV MY-CYT-00088 Mar/2022
51 Minutes - 3 Chapters Evidence of Immune Checkpoint Blockade with Pembrolizumab for R/R cHL BACK TO WEBCASTS MY-KEY-00364 Oct/2020
37 Minutes - 4 Chapters What Have We Learned in 2019 on Combination Treatments for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) BACK TO WEBCASTS MY-KEY-00210 02/20
43 Minutes - 1 Chapter Redefining Survival with IO-TKI Strategy in Renal Cell Carcinoma (RCC) Overview The emergence of IO-TKI combination therapy has redefined survival expectations in advanced RCC. Professor Brian Rini provides a comprehensive […]
51 Minutes - 2 Chapters Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) BACK TO WEBCASTS MY-KEY-00147 09/19
31 Minutes - 4 Chapters Post WCLC and ESMO 2019 Update: Pembrolizumab in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) BACK TO WEBCASTS MY-KEY-00155 10/19